Brief Intervention for OCD Fears

New York State Psychiatric Institute

Status and phase: Withdrawn; Phase 4

Conditions: Obsessive-compulsive Disorder

Treatments: Drug: Placebo; Drug: Propanolol

Study type: Interventional

Funder types: Other

Identifiers

NCT02790710

7293 (OCD)

Details and patient eligibility

About

The study will test the efficacy of propranolol or placebo, administered after reactivation of a previously acquired obsessive-compulsive disorder (OCD) fear, in reducing fear and avoidance in OCD.

Full description

Twenty subjects with OCD will be enrolled in the study. Participants will complete baseline assessments of fear and avoidance. Participants will be randomly assigned to a single dose of propranolol 40mg or placebo, administered immediately after a fear reactivation procedure. Primary outcome assessment will be OCD symptoms and avoidance behavior in a behavioral avoidance task 2 weeks after the intervention

Sex: All

Ages: 18 to 60 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Principal Diagnosis of Obsessive-Compulsive Disorder

Exclusion criteria

• History of other serious psychiatric disorder
• Current Major Depressive Disorder
• Women who are pregnant or nursing
• Current use of psychiatric medication
• Persons planning to start another treatment during the study period
• Any significant medical condition that might increase the risk or participation or use of medications that might negatively interact with propranolol

Trial design

Primary purpose: Other

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

0 participants in 2 patient groups, including a placebo group

Propanolol

Experimental group

Description:

Propranolol 40 mg capsule, given once after fear reactivation procedure

Treatment:

Drug: Propanolol

Placebo capsule

Placebo Comparator group

Description:

Placebo capsule, given once after fear reactivation procedure

Treatment:

Drug: Placebo